Johannes C Rothlind1, Michele K York2, Kim Carlson3, Ping Luo3, William J Marks4, Frances M Weaver5, Matthew Stern6, Kenneth Follett7, Domenic Reda3. 1. Mental Health Service, San Francisco VA Medical Center and Department of Psychiatry, University of California, San Francisco, California, USA. 2. Department of Neurology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA. 3. Hines VA Hospital, Cooperative Studies Coordinating Center, Hines, Illinois, USA. 4. Department of Neurology, San Francisco, California, USA. 5. Hines VA Hospital, Center for Management of Complex Chronic Care, Hines, Illinois, USA Loyola University Stritch School of Medicine, Maywood, Illinois, USA. 6. University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA. 7. Iowa City VA Medical Center, Iowa City, Iowa, USA University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abstract
BACKGROUND:Deep brain stimulation (DBS) improves motor symptoms in Parkinson's disease (PD), but questions remain regarding neuropsychological decrements sometimes associated with this treatment, including rates of statistically and clinically meaningful change, and whether there are differences in outcome related to surgical target. METHODS:Neuropsychological functioning was assessed in patients with Parkinson's disease (PD) at baseline and after 6 months in a prospective, randomised, controlled study comparing best medical therapy (BMT, n=116) and bilateral deep brain stimulation (DBS, n=164) at either the subthalamic nucleus (STN, n=84) or globus pallidus interna (GPi, n=80), using standardised neuropsychological tests. Measures of functional outcomes were also administered. RESULTS: Comparison of the two DBS targets revealed few significant group differences. STN DBS was associated with greater mean reductions on some measures of processing speed, only one of which was statistically significant in comparison with stimulation of GPi. GPi DBS was associated with lower mean performance on one measure of learning and memory that requires mental control and cognitive flexibility. Compared to the group receiving BMT, the combined DBS group had significantly greater mean reductions at 6-month follow-up in performance on multiple measures of processing speed and working memory. After calculating thresholds for statistically reliable change from data obtained from the BMT group, the combined DBS group also displayed higher rates of decline in neuropsychological test performance. Among study completers, 18 (11%) study participants receiving DBS displayed reliable decline by multiple indicators in two or more cognitive domains, a significantly higher rate than in the BMT group (3%). This multi-domain cognitive decline was associated with less beneficial change in subjective ratings of everyday functioning and quality of life (QOL). The multi-domain cognitive decline group continued to function at a lower level at 24-month follow-up. CONCLUSIONS: In those with PD, the likelihood of significant decline in neuropsychological functioning increases with DBS, affecting a small minority of patients who also appear to respond less optimally to DBS by other indicators of QOL. TRIAL REGISTRATION NUMBER: NCT00056563 and NCT01076452. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
BACKGROUND: Deep brain stimulation (DBS) improves motor symptoms in Parkinson's disease (PD), but questions remain regarding neuropsychological decrements sometimes associated with this treatment, including rates of statistically and clinically meaningful change, and whether there are differences in outcome related to surgical target. METHODS: Neuropsychological functioning was assessed in patients with Parkinson's disease (PD) at baseline and after 6 months in a prospective, randomised, controlled study comparing best medical therapy (BMT, n=116) and bilateral deep brain stimulation (DBS, n=164) at either the subthalamic nucleus (STN, n=84) or globus pallidus interna (GPi, n=80), using standardised neuropsychological tests. Measures of functional outcomes were also administered. RESULTS: Comparison of the two DBS targets revealed few significant group differences. STN DBS was associated with greater mean reductions on some measures of processing speed, only one of which was statistically significant in comparison with stimulation of GPi. GPi DBS was associated with lower mean performance on one measure of learning and memory that requires mental control and cognitive flexibility. Compared to the group receiving BMT, the combined DBS group had significantly greater mean reductions at 6-month follow-up in performance on multiple measures of processing speed and working memory. After calculating thresholds for statistically reliable change from data obtained from the BMT group, the combined DBS group also displayed higher rates of decline in neuropsychological test performance. Among study completers, 18 (11%) study participants receiving DBS displayed reliable decline by multiple indicators in two or more cognitive domains, a significantly higher rate than in the BMT group (3%). This multi-domain cognitive decline was associated with less beneficial change in subjective ratings of everyday functioning and quality of life (QOL). The multi-domain cognitive decline group continued to function at a lower level at 24-month follow-up. CONCLUSIONS: In those with PD, the likelihood of significant decline in neuropsychological functioning increases with DBS, affecting a small minority of patients who also appear to respond less optimally to DBS by other indicators of QOL. TRIAL REGISTRATION NUMBER: NCT00056563 and NCT01076452. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
ELECTRICAL STIMULATION; MOVEMENT DISORDERS; NEUROPSYCHOLOGY; NEUROSURGERY; PARKINSON'S DISEASE
Authors: Kelly A Mills; Zoltan Mari; Gregory M Pontone; Alexander Pantelyat; Angela Zhang; Nadine Yoritomo; Emma Powers; Jason Brandt; Ted M Dawson; Liana S Rosenthal Journal: Parkinsonism Relat Disord Date: 2016-09-27 Impact factor: 4.891
Authors: Adam Nassery; Christina A Palmese; Harini Sarva; Mark Groves; Joan Miravite; Brian Harris Kopell Journal: Curr Neurol Neurosci Rep Date: 2016-10 Impact factor: 5.081
Authors: Lucio Marinelli; Angelo Quartarone; Mark Hallett; Giuseppe Frazzitta; Maria Felice Ghilardi Journal: Clin Neurophysiol Date: 2017-04-09 Impact factor: 3.708
Authors: Jutta S Mayer; Joseph Neimat; Bradley S Folley; Sarah K Bourne; Peter E Konrad; David Charles; Sohee Park Journal: Neurocase Date: 2016-06-23 Impact factor: 0.881
Authors: Hannah L Combs; Bradley S Folley; David T R Berry; Suzanne C Segerstrom; Dong Y Han; Amelia J Anderson-Mooney; Brittany D Walls; Craig van Horne Journal: Neuropsychol Rev Date: 2015-10-12 Impact factor: 7.444
Authors: Ka Loong Kelvin Au; Joshua K Wong; Takashi Tsuboi; Robert S Eisinger; Kathryn Moore; Janine Lemos Melo Lobo Jofili Lopes; Marshall T Holland; Vanessa M Holanda; Zhongxing Peng-Chen; Addie Patterson; Kelly D Foote; Adolfo Ramirez-Zamora; Michael S Okun; Leonardo Almeida Journal: Neurol Ther Date: 2020-11-02